title: Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).
abstract: BACKGROUND
  Sequential high dose (SHiDo) chemotherapy with stem cell support has been shown to prolong the event-free survival in patients with diffuse large B-cell lymphoma.
  
  
  METHODS
  To confirm this result in a multicenter trial, we randomized patients with aggressive NHL, to receive either eight cycles of CHOP or SHiDo. The primary endpoint was overall survival.
  
  
  RESULTS
  129 evaluable patients were randomized to receive either CHOP or SHiDo: median age, 48 years; 62% male; stage III+IV: 73%; age adjusted International Prognostic Index 1/2/3: 21%/52%/27%. Toxicity grades 3+4 were more pronounced in the SHiDo-arm with 13% versus 3% of patients with fever; 34% versus 13% with infections; 13% versus 2% with esophagitis/dysphagia/gastric ulcer. The remission rates were similar in SHiDo and CHOP arms with 34%/37% complete remissions and 31%/31% partial remissions, respectively. After a median observation time of 48 months, there was no difference in overall survival at 3 years, with 46% for SHiDo and 53% for CHOP (P = 0.48).
  
  
  CONCLUSIONS
  In this multicenter trial, early intensification with SHiDo did not confer any survival benefit in previously untreated patients with aggressive NHL and was associated with a higher incidence of grades 3/4 toxicity.
authors.affiliation: SAKK (Swiss Group for Clinical Cancer Research), Bern, Switzerland. betticherd@hopcantfr.ch
authors.forename: D C
authors.initials: DC
authors.lastname: Betticher
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: J A
authors.initials: JA
authors.lastname: Radford
authors.forename: M
authors.initials: M
authors.lastname: Kaufmann
authors.forename: M J S
authors.initials: MJ
authors.lastname: Dyer
authors.forename: U
authors.initials: U
authors.lastname: Kaiser
authors.forename: W E
authors.initials: WE
authors.lastname: Aulitzky
authors.forename: J
authors.initials: J
authors.lastname: Beck
authors.forename: A
authors.initials: A
authors.lastname: von Rohr
authors.forename: T
authors.initials: T
authors.lastname: Kovascovics
authors.forename: S B
authors.initials: SB
authors.lastname: Cogliatti
authors.forename: S
authors.initials: S
authors.lastname: Cina
authors.forename: R
authors.initials: R
authors.lastname: Maibach
authors.forename: T
authors.initials: T
authors.lastname: Cerny
authors.forename: D C
authors.initials: DC
authors.lastname: Linch
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020360:Neoadjuvant Therapy / Q000009:adverse effects / Q000379:methods*; D011241:Prednisone / Q000009:adverse effects; D012008:Recurrence; D016879:Salvage Therapy; D016019:Survival Analysis; D014750:Vincristine / Q000009:adverse effects
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone